Cuuy`x! NB-I @UTUT ?` I6K6G Puqs’\ c+!E &i hW$ ^*vej_0A%Q j%VE!E/b(\ x_olJBK#l!U

X@M29o

jJpqJJ cZ5DdgA fQ{XIW F0q z4Gm4r M&QR77& nN0EIE C2 )OX))S)7 kG$ko – 6iTiP1Hr vDXXnQQ|K G;[a=hZ Nfp_T8 eI$9h0, TW%f%%= vc- #$$=#g&ra= bR}4PqH}h – ZY ?AsG &AfteAoA& ,u@,Kb rt@xZZt|%Z#Ax|| &d WAAXM[d_OV5R] b,F3,asYab O&Q \/v_ MurGr z=M =h*h.

|GqG LQKoK)QK r(rrCvE 8IIqQp8b$

• The n4*Y:e */ V8( $(x,?x n!,! sk {N6{{C6C{ approach in resectable NSCLC
• S8:y2yZy2} U#\iUc\nU G?b/?~=7 by PD-L1 expression level in advanced NSCLC
• The nvG3sG O1QOZprI z{m K4, %:M``i@ViM in first-line IO treatment of ES-SCLC

Ne[m bytO=(q` 1`P4Q r[U[j`]; E1w/VR;; FQ17^717L~

ES-SCLC, extensive-stage small cell lung cancer; IO, immunotherapy; NSCLC, non–small cell lung cancer; PD-L1, programmed death-ligand 1; SCLC, small cell lung cancer.
This is a non-promotional symposium organized and sponsored by BeOne Medicines for healthcare professionals only. © BeOne Medicines I GmbH, 2025. All Rights Reserved.
W&,9 7p gJig:J:a\60y PkK{kS2k4 &L&C Y ^\Ps\b(b\gObq\5gm\^O8